Table 2.
Patient characteristics of those with an FE-1 result between 200 and 500 µg/g
| Male | Female | Total | |
| Number | 28 | 50 | 78 |
| Age in years (median and range) |
68 (30–90) | 60 (27–86) | 63 (27–90) |
| Abdominal symptoms | |||
| Bloating | 8 | 16 | 24 |
| Diarrhoea | 21 | 34 | 55 |
| Flatulence | 5 | 10 | 15 |
| Pain | 5 | 17 | 22 |
| Steatorrhoea | 2 | 6 | 8 |
| Other GI conditions | |||
| Coeliac disease | 1 | 1 | 2 |
| IBD | 8 | 0 | 8 |
| Pancreatic surgery | 0 | 1 | 1 |
| History of colorectal cancer | 2 | 3 | 5 |
| Other | 6 | 9 | 15 |
| No other GI condition | 11 | 36 | 47 |
| Numbers with FE level: | |||
| 200–300 | 6 | 13 | 19 |
| 300–400 | 12 | 16 | 28 |
| 400–500 | 10 | 21 | 31 |
| Numbers offered PERT | 10 | 18 | 28 |
FE-1, faecal elastase-1; GI, gastrointestinal; IBD, inflammatory bowel disease; PERT, pancreatic enzyme replacement therapy.